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Communicating risk
We as doctors are not alone
Editor—Risk is a crucial part of current
medical practice, as clarified in the editorials
by Edwards, Godolphin, and Thornton.1–3 It is
a subject that we all have to deal with day to
day, and knowing that others are grappling
with these difficult ideas is refreshing. The
debate, however, needs to be
widened further.
As medical practitioners
we are not alone in facing
uncertainty and risk. Every-
one involved in decision
making faces the same prob-
lem. Whether it is the risk
posed by an Iraqi regime
headed by Saddam Hussein,
the likelihood of a large
meteorite striking the earth,
or the chances of an Intercity
125 crashing, everyone is
confronted with uncertainty
and risk.
The debate on risk needs
to be taken beyond the confines of medical
journals and into the general media, the
House of Commons, and school classrooms.
Only when the concepts of risk and
uncertainty become familiar to the public at
large can we as doctors hope to have an
informed discussion with people who come
to us asking for advice.
Thomas W V Daniels respiratory specialist registrar
Southampton General Hospital, Southampton
SO16 6YD
t.daniels@virgin.net
Competing interests: None declared.
1 Edwards A. Communicating risks. BMJ 2003;327:691-2.
(27 September.)
2 Godolphin W. The role of risk communication in shared
decision making. BMJ 2003;327:692-3. (27 September.)
3 Thornton H. Patients’ understanding of risk. BMJ
2003;327:693-4. (27 September.)
Compulsory measures can work
Editor—Thank you for devoting an issue of
the BMJ to the important topic of communi-
cation and public perception of risk. As a
public health doctor, I have long puzzled
over the apparent dissonance between
statistical and public interpretation of risk.
Risks imposed by others may be less
acceptable than risks under individual
control. In the examples covered by Bellaby,1
injuries to child passengers could be
perceived by parents as under their own
control. Measles, mumps, and rubella vacci-
nation2 and variant Creutzfeldt-Jakob dis-
ease are, however, perceived as imposed by
authority.
When comparing the risk of death from
smoking and air travel, statistics tell us that
air travel is incredibly safe and that smoking
is not. Plane crashes induce enormous pub-
lic fear, yet some 340 jumbo jets would have
to crash every year to equal the toll from
smoking in the United King-
dom. The media, and hence
the public, seem more fright-
ened by unusual and imme-
diate events. Smoking is an
every day occurrence and
takes many years to kill. Plane
crashes are rare and happen
in a matter of hours after take
off.
Bellaby argues that in a
post-war democracy, compul-
sion cannot work and con-
cordance through two way
communication is the only
way forward. Although con-
cordance is preferable, compulsion can
work well: seat belt legislation. After it was
introduced in 1988 this compulsory, effec-
tive health measure did not generate mass
riots or failed compliance.3–5 Research into
the above issues could contribute to the
implementation of effective public health
programmes, through better communica-
tion, in today’s Britain.
Rosemary J Geller director of health strategy
Shropshire and Staffordshire Health Authority,
Stafford ST16 3SR
rosemary.gellerparkhouse@freeserve.co.uk
The views expressed here are those of the author and
do not necessarily represent the views or policies of
Shropshire and Staffordshire Health Authority.
Competing interests: None declared.
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Patients often have complex
understanding of risk
Editor—Why do doctors make such heavy
weather of risk? The discussion of risk
assessment and communication still slips
into patronising patients and oversimplify-
ing issues.1 We think that individual deci-
sions are almost always reasoned and that
patients often have more complex under-
standing of risk than their doctors.
There are two dimensions to under-
standing health risks from a citizen’s
perspective: their estimation of the probabil-
ity and impact of any action or inaction, and
their position on a spectrum from conform-
ist to dissenting attitude.
Driving children to school does expose
them to the risk of road crashes, but the
probability of this happening is decreasing
as the volume of traffic rises and the rate of
serious crashes falls. The impact of accidents
can be reduced by individual action (careful
driving), technological innovation (safer
cars), and social measures (traffic calming).
Similarly, the possibility of a connection
between the vaccine for measles, mumps,
and rubella and autism is understood as a
risk of a highly unlikely event that will have a
profound impact, whereas measles, mumps,
and rubella will have a low impact, despite
being increasingly likely.
An emerging conception of the fit body
emphasises that the immune system (if well
brought up) will respond flexibly to
challenge, without need for potentially haz-
ardous immunisation. This new common
sense about health emphasises autonomy
and responsibility, and resonates with
conventional wisdom about personal and
economic flexibility. What alternative com-
mon sense can BMJ readers offer? Herd
immunity is hardly an enticing idea for
robust individualists.
Steve Iliffe reader in general practice
Royal Free and University College London Medical
School, London NW3 2PF
s.iliffe@pcps.ucl.ac.uk
Jill Manthorpe professor of social work
Social Care Workforce Research Unit, Franklin
Wilkin Building, King’s College, London SE1
Competing interests: None declared.
1 Bellaby P. Communication and miscommunication of risk:
understanding UK parents’ attitudes to combined MMR
vaccination. BMJ 2003;327:725-8. (27 September.)
Journalists take note
Editor—Gigerenzer and Edwards provide
us with a succinct summary of everything
that is wrong with communicating risk both
within the medical profession and to the
public at large.1 What is more, they suggest
comparatively easy ways of improving the
current sad state of confusion and mis-
understanding, by using natural frequencies
or absolute risks whenever possible, rather
than relative risks alone.
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My concern is that the public invariably
gets its medical information from the media
first, and that journalists who scan the medi-
cal press often clearly do not understand the
statistics that they are quoting. Particularly
with the results of drug trials, the relative risk
reduction is quoted (as it is the figure which
looks the most impressive) without any
reference to natural frequency or absolute
risk. Relative risk has very little meaning
unless it is framed by the natural frequency
of the event considered.
This problem was apparent with the
splash headlines recently produced for
hormone replacement therapy as a result of
the “million women study”—newspapers
referred to combined hormone replacement
therapy doubling the risk of breast cancer,
without saying what the risk was. Figures for a
worst case scenario would be helpful. For
example, “At the age of 60 the risk of breast
cancer in a woman who has never taken hor-
mone replacement is 3.8 for every 100
women: for a woman of 60 who has been tak-
ing combined hormone replacement for 10
years the risk increases to 5.7 in 100 women.”
Adding the positive frame to these figures
(that 94.3 in 100 women who had taken hor-
mone replacement for 10 years did not get
breast cancer) also helps clarify the risk.
Maybe it also helps clarify the recent
report in the newspapers that despite the
widespread retreat from hormone replace-
ment therapy in the public at large, 80% of
women consultants continue to take it while
being fully aware of these absolute risks.
David S Rivers general practitioner principal
Hastings House Medical Centre, Wellesbourne,
Warwick CV35 9NF
drivers@netcomuk.co.uk
Competing interests: None declared.
1 Gigerenzer G, Edwards A. Simple tools for understanding
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(27 September.)
Journalists have responsibility to report
risks in context
Editor—Easton discussed health risk
reporting in the media.1 A lot can be learnt
about people’s perceptions of risk by exam-
ining lottery play. This in itself may have
implications for how journalists report risk
probabilities in media settings.
The probability of winning lottery prizes
are the basic risk dimensions that may help
determine whether a person gambles on a
particular activity in the first place. The ordi-
nary “social gambler” probably does not
think about the probability of winning.What
most people will concentrate on is the
amount that could be won, rather than the 1
in 14 million probability of winning.
How probability operates is generally
not understood. Some of the general public
seem not to believe that the probability of
the numbers 1, 2, 3, 4, 5, and 6 being picked
from the 49 balls is equally as likely as any
other sequence of six numbers. Some also
believe that future predictions can be based
successfully on previous draws.
People tend to overestimate positive
outcomes and underestimate negative ones.
This may have implications for reporting
health risks in the media. For example, if
someone is told they have a one in fourteen
million chance of being killed on any
particular Saturday night they would hardly
give it a second thought because the chances
of anything untoward happening are infini-
tesimal. However, given the same probability
of winning the National Lottery, people sud-
denly become over optimistic.
The public’s understanding of risk prob-
ability could be improved. However, journal-
ists still have a responsibility to report risks
in context. Too many reports seem to say, for
example, “Coffee drinkers are three times as
likely to develop X” while omitting to point
out that the risks are still infinitesimal.
Mark D Griffiths professor of gambling studies
Psychology Division, Nottingham Trent University,
Nottingham NG1 4BU
mark.griffiths@ntu.ac.uk
Competing interests: None declared.
1 Easton G. Reporting risk—that’s entertainment. BMJ
2003;327:256. (27 September.)
Doctor’s recommendation is decision
making in uncertain conditions
Editor—In his editorial Edwards discussed
the communication of risk.1 Many times in
health care decisions must be made under
conditions of uncertainty, such as choosing
the type of breast cancer surgery when the
staging of the disease has yet to be confirmed.
Under such circumstances we have
found that Chinese women facing choice
between mastectomy and lumpectomy lack
sufficient information on risks and out-
comes and, as such, tend to use an intuitive
rather than rational decision making
approach.2 3 In the absence of clear outcome
data, these women want their surgeon to
make a clear recommendation about a pref-
erence for treatment. Such a recommen-
dation may be being used as an “experience”
proxy for lack of risk estimation.
Richard Fielding deputy director
fielding@hkusua.hku.hk
Wendy W T Lam director
Centre for Psycho-Oncology Research and
Teaching, 5/F, Academic and Admin Block, Faculty
of Medicine Building, University of Hong Kong, 21
Sassoon Road, Pokfulam, Hong Kong SAR, China
Competing interests: None declared.
1 Edwards A. Communicating risks. BMJ 2003;327:691-2.
(27 September.)
2 Lam WWT, Fielding R. The evolving experience of illness
for Chinese women with breast cancer: A qualitative study.
Psycho-Oncol 2003;12:127-40.
3 Lam WWT, Fielding R, Chan M, Chow L, Ho EYY. Patient
participation and satisfaction with treatment decision
making in Chinese women with breast cancer. Breast Can-
cer Res Treatment 2003;80:171-80.
But does it work, Doctor?
Editor—A theme issue of the BMJ urged
practitioners to communicate risk, and share
decision-making with their patients, but this
is not always straightforward. Godolphin
says that there are comparatively few
medical problems for which good risk infor-
mation is available.1 I would add that, even
when there is substantial research, the
findings do not always answer those
questions most relevant to patients.2 3
We examined research conducted into
the available treatments for menorrhagia, in
the course of designing a decision aid to
support treatment decisions in our current
randomised controlled trial (MENTIP: men-
orrhagia, treatment, information, and pref-
erences). The studies included five Cochrane
reviews, five other reviews, 17 randomised
controlled trials, and six cohort studies.
Even with all this available evidence it
was still remarkably difficult to answer the
simple question from patients, “Does it work,
Doctor?” Although menorrhagia is defined
objectively as menstrual blood loss of
greater than 80 ml, the actual experience of
symptoms is highly variable.3 Many research
studies reported treatment outcomes in
terms of percentage change in menstrual
blood loss, but percentage reduction would
mean different things to different women
and may not be a good measure of the per-
ceived benefit of treatment.
Perhaps it would be helpful if research-
ers designing randomised controlled trials
of treatments, for any condition, could
include, among their objective outcomes,
some more global, patient centred outcomes
such as “satisfaction with treatment,” “will
continue with treatment,” or “symptoms bet-
ter.” This would help us answer the patient’s
questions, including “Does it work, Doctor?”
and “What’s the evidence for that, Doctor?”
Joanne Protheroe general practitioner
National Primary Care Research and Development
Centre, University of Manchester, Manchester
M13 9PL
joanne.protheroe@man.ac.uk
Competing interests: None declared.
1 Godolphin W. The role of risk communication in shared
decision making. BMJ 2003;327:692-3. (27 September.)
2 Edwards A, Elwyn G. Evidence-based patient choice: inevitable
or impossible? Oxford: Oxford University Press, 2001.
3 Higham JM. Clinical associations with objective menstrual
blood loss. Eur J Obstet Gynaecol Reprod Biol 1999;82:73-76.
Drug sales in four European
countries still differ
Editor—The box shows, by value, the top
selling pharmaceutical products that are
common to Italy, France, Germany, and the
United Kingdom. In 1992,1 1996,2 and 2001
few products were prescribed in all four
countries. Nineteen active substances were
common to three countries, 17 to two coun-
tries, and 63 were on only one country’s list.
Several classes of drugs were repre-
sented in all four countries but with different
products. For example, angiotensin convert-
ing enzyme inhibitors were prescribed as
enalapril in Italy, lisinopril in the United
Kingdom, and ramipril in Germany and
France. Selective serotonin reuptake inhibi-
tors were paroxetine and sertraline in Italy,
the United Kingdom, and France; amoxicil-
lin was common in Italy, the United
Kingdom, and France, but no antibiotic fea-
tured in the top 50 in Germany. The
preferred fluoroquinolone was cipro-
floxacin everywhere but in France.
In Italy several antibiotics stand out—
ceftriaxone, clarithromycin, and azithro-
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mycin—as do three benzodiazepines, bical-
utamide, tamsulosin, and triptorelin (for
prostate cancer). In the United Kingdom the
non-steroidal anti-inflammatory drugs were
represented by morniflumate; goserelin was
the preferred drug for prostate cancer; and
the list included two epilepsy drugs (lamo-
trigine and gabapentin) and the migraine
drug sumatriptan.
Germany has a large market for omepra-
zole, pantoprazole, and esomeprazole;
nadroparine; and certoparin. Also included
are filgrastim, a granulocyte colony stimulat-
ing factor; glimepiride, a hypoglycaemic
agent; disodium pamidronate for osteolytic
lesions induced by cancer metastases; and
mirtazapine, a presynaptic -2 noradrenergic
antagonist, for depressive illness.
In France fenofibrate, a hypocholester-
aemic agent, competes with the statins.
Cefpodoxime and roxythromycin predomi-
nate among the antibiotics, buprenorphine
was the preferred analgesic, and gliclazide
was the bestseller for type 2 diabetes.
Donepezil, for Alzheimer’s disease, and riba-
virin for hepatitis C are other peculiarities of
the French market.
Over the past 10 years the quality of
drug expenditure has improved because the
number of drugs with insufficient evidence
of efficacy has dropped in all four countries:
from 25 in 1992 to 11 in 1996 and 9 in
2001.1 2
European efforts to establish a central-
ised procedure and common information
on approved drugs in the past 10 years have
not unified drug use. Manufacturers’ pro-
motional activities and doctors’ attitudes,
rather than differences in disease, are still
the main factors governing the pharmaceu-
tical market.
Silvio Garattini director
Istituto di Ricerche Farmacologiche “Mario Negri,”
Via Eritrea, 62, I-20157 Milan, Italy
garattini@marionegri.it
Livio Garattini chief
Centro di Economia Sanitaria Angelo e Angela
Valenti, Villa Camozzi, Ranica (BG), Italy
Competing interests: None declared.
1 Garattini S, Garattini L. Pharmaceutical prescriptions in
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1998;317:947.
Real time assay of Aspergillus
should be used in SARS
patients receiving
corticosteroids
Editor—No consensus currently exists on
treatment of the severe acute respiratory syn-
drome (SARS). Wong et al reported that all
patients with SARS received broad spectrum
antibiotics and a combination of ribavirin and
prednisolone.1 Intravenous methylpred-
nisolone at high dosage was used in patients
with respiratory distress or progressive
consolidations in a chest radiograph.
However, the treatment of SARS with
ribavarin and corticosteroids remains con-
troversial.2 Corticosteroids are administered
to suppress a possible cytokine storm, which
may worsen the lung injury caused by the
infectious agent.2 But using corticosteroids
with possibly ineffective antiviral agents in
patients with virus induced pneumonitis can
be hazardous.2
If corticosteroids are administered doc-
tors must always be aware of complications
such as superinfections with Aspergillus,3 a
known complication in any patient receiving
corticosteroids.4 Patients with SARS receiv-
ing corticosteroids should therefore be
monitored for aspergillosis.
Since Aspergillus usually grows slowly
on culture (taking up to six days) and is
characterised by low sensitivity, we advise
introducing an assay using amplification by
the polymerase chain reaction, performed in
real time, to detect 18SrRNA Aspergillus
specific sequences in specimens obtained by
bronchoalveolar lavage. Such an assay
should be used in association with galacto-
mannan antigen detection by enzyme linked
immunosorbent assay (ELISA), as described
by Sanguinetti et al.5
This promising method for diagnosing
aspergillosis is highly sensitive, fast, specific,
and non-invasive. It is certainly less
traumatic than lung biopsy.4 5
Ya Ping Wu researcher
Department of Haematology, University Medical
Centre Utrecht, 3584CX Utrecht, Netherlands
ywu@azu.nl
Ran Wei professor
Basic Medical Science Institute, Taishan Medical
College, Taian, Shandong, China 271000
Jan Verhoef professor
Eijkman-Winkler Centre for Medical Microbiology,
Infectious Diseases and Inflammation, University
Medical Centre Utrecht
Competing interests: None declared.
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N Engl J Med 2003;348:2034-5.
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4 Muller FM, Trusen A, Weig M. Clinical manifestations and
diagnosis of invasive aspergillosis in immuno-
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5 Sanguinetti M, Posteraro B, Pagano L, Pagliari G, Fianchi
L, Mele L, et al. Comparison of real-time PCR,
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diagnosis of invasive pulmonary aspergillosis. J Clin Micro-
biol 2003;41:3922-5.
Prognosis for South Asian and
white patients with heart
failure in the United Kingdom
Counterintuitive findings on heart failure
in South Asians may be artefactual
Editor—Blackledge et al recognise some of
their findings as counterintuitive—for exam-
ple, a huge excess of hospital admissions for
heart failure in South Asians and yet a better
outcome.1 Such results could be artefactual.2
They use cases from 1998 to 2001 but
the population in 1991. Were the ethnic
codes used in hospital data the same as
those used in the 1991 census, and were the
populations called South Asian the same in
the numerator and denominator? Table 1
shows that 85% of South Asian patients lived
in the most deprived areas (Q5), compared
with 38% of white patients. Figure 1 shows
an age adjusted ratio for heart failure admis-
sion of about 2.8 in men and 4.3 in women,
in apparent contradiction to the figures
given in the abstract (3.8 and 5.2). There are
typographical errors in table 2.
We offer three alternative, testable expla-
nations detailed in our electronic response.3
Firstly, South Asians’ excess of heart fail-
ure out of proportion to coronary mortality
or morbidity4 may be an artefact. For exam-
ple, South Asians live in the inner city close
to the local hospitals, while white patients
are scattered across the city so may be less
likely to be admitted to hospital with heart
failure or more likely to be admitted outside
Leicestershire.
Secondly, the better outcome in South
Asians results from residual confounding by
age.
Thirdly, the better outcome in the most
deprived quintile reflects the high pro-
portion of younger South Asians, with
incomplete control of ethnic group and age
as potential confounding factors.
Raj Bhopal professor
Raj.Bhopal@ed.ac.uk
Colin Fischbacher clinical research fellow
Public Health Sciences, University of Edinburgh,
Edinburgh EH8 9AG
Popular drugs common to Italy, the
United Kingdom, Germany, and
France
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Deprivation gradient in mortality should
not be dismissed as artefactual
Editor—Blackledge et al report that, coun-
terintuitively, socially deprived patients with
heart failure have a better all cause mortality
risk.1 This contradicts a large previous study
in the United Kingdom showing a clear
socioeconomic gradient in mortality risk
favouring the least deprived patients.2
Blackledge et al suggest that their
finding may be an artefact of the deprivation
index they used (index of multiple depriva-
tion 2000). However, misclassification error
resulting from the use of any ecological dep-
rivation index would influence results
towards parity rather than produce a clear
socioeconomic gradient. Although the
results are significant only for the most
deprived group, a test for trend using the
deprivation score as a continuous variable is
likely to have produced a significant result
and could have been more informative.3
As the authors state, adverse health out-
comes are concentrated in the elderly popu-
lation subgroups of any given geographi-
cally defined population. Nevertheless, area
based deprivation indices for the United
Kingdom consistently predict adverse
health outcomes at the individual level.4
An alternative hypothesis is that the
observed prognostic variation might reflect
differences in the cause of heart failure in
different deprivation groups. The more
deprived groups may contain comparatively
more patients with heart failure due to valve
disease, hypertension, alcoholism, and
arrhythmias and comparatively fewer with
coronary artery disease, which has the poor-
est prognosis.5 The exact causes of the socio-
economic differences in mortality observed
in this study merit further investigation and
should not on current evidence be dismissed
as artefactual.
G Lyratzopoulos lecturer in public health
georgios.lyratzopoulos@man.ac.uk
R F Heller professor of public health
Evidence for Population Health Unit, School of
Epidemiology and Health Sciences, Medical School,
University of Manchester, Manchester M13 9PT
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Authors’ reply
Editor—Population estimates from the
1991 census—the only data available to
us—could introduce error in calculating age
standardised rates and ratios, particularly for
subpopulations with differing age structures.
Using 2001 census data, we found that
admission rates in the South Asian popula-
tion were more than twofold higher for both
men and women.
The reason for the higher standardised
admission rates for heart disease for the city
is debatable.1 Our system captures all hospi-
tal admissions for the population of
Leicestershire, irrespective of the location of
the admission. Missing out of county data
could not have been a source of error.
We are confident of the validity of
assignment of ethnic group as hospital
codes were validated for all cases in the sur-
vival cohort. Age was a significant predictor
of mortality, and due care was taken to
obtain the best fitting model. We recognise
that severity of heart failure at admission
and details of clinical management will
affect survival, but routine data do not
capture this information.
We agree that the relation between dep-
rivation and heart failure survival is puz-
zling. We are confident that categorising the
index is valid. In keeping with published
data, modelling all cause survival with the
index gave an estimated hazard ratio of 0.93
(95% confidence interval 0.88 to 0.98) and a
7% improvement in survival between quin-
tiles 2-4 and 1 (least deprived) and a 14%
improvement between quintiles 5 and 1.
That coronary heart disease is less
prevalent in the most deprived groups
seems unlikely. Indeed 23% of those from
the least deprived and 25% from the most
deprived cohorts had such a previous hospi-
tal diagnosis.
The impact of social disadvantage meas-
ures on survival in heart failure has been
little investigated. MacIntyre et al showed a
6-10% increase in hazard ratio in the most
deprived areas.2 A life course approach to
determining patients’ social status could
have given us different results.3 4 However,
our results are important in showing the
complexity of the relation between social
disadvantage and how it is measured.
Iain Squire senior lecturer in medicine
is11@leicester.ac.uk
James Newton clinical research fellow
Department of Cardiovascular Therapeutics,
University of Leicester, Leicester LE2 4NU
Hanna Blackledge public health analyst
Department of Health Informatics, Leicestershire,
Northamptonshire and Rutland Strategic Health
Authority
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Adherence to advance directives
GMC’s advance directive is commendable
Editor—Thompson et al’s article on adher-
ence to advance directives is a telling explo-
ration of an increasingly relevant issue.1 The
vignette they constructed was comprehen-
sive and robust, leaving no reasonable
person in any doubt about the nature and
severity of conditions for which the patient
would refuse intervention.
The arguments for treating the patient
in the face of such a clear instruction seem
to amount to no more than seeking
loopholes, or high handedly insisting that
doctors know best. Both sit uneasily in an
era when doctors call for patients to take
more responsibility for their illnesses.
Some of the variation in adherence to
patients’ wishes which they identify may be
because, until recently, there was a perceived
lack of explicit guidance on what doctors are
to do when faced with what, in the United
Kingdom, is a contemporary development.
The General Medical Council has
recently produced thorough guidelines that
intensivists have found useful.2 3 These say
that any valid advance refusal is legally bind-
ing and must be respected when it is
applicable to the patient’s present circum-
stances and when there is no reason to
believe that the patient has changed his or
her mind.
In contrast, doctors may be lulled into a
false sense of security if they take at face
value the conclusion of Thompson et al that
successful prosecution is unlikely if an
advance directive is ignored. The guidelines
remove much room for manoeuvre clini-
cians once thought they had when following
patients’ instructions. The GMC has pro-
duced a compelling advance directive itself,
which is to be commended to all those
involved in making such decisions.
Andrew G Higgs consultant in anaesthesia and
intensive care medicine
North Cheshire NHS Trust, Warrington WA5 1QG
andyhiggs@doctors.org.uk
Competing interests: None declared.
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Quality of life matters
Editor—I am disturbed by the implication
that a sizeable minority of the participants in
the study by Thompson et al would
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disregard an advance directive.1 Surely the
reason for prescribing active treatment in
the scenario presented is that there is some
doubt about whether the conditions covered
by the directive apply.
Decisions such as this are likely to be
presented to doctors with increasing fre-
quency, often in an emergency context in
which the decision has to be made without
previous knowledge of the patient. In this
situation the family, particularly those in
regular contact, may be very helpful in inter-
preting the patient’s wishes, although it must
be borne in mind that relatives may have
their own financial or emotional agenda.
The decision might lie with a doctor who
knows the patient well and who may even
have countersigned the advance directive. In
such a case his or her knowledge will guide
the decision making. However, with an eight
year interval and a move to a nursing home,
together with increased mobility among
general practitioners, this is unlikely. This is
a grey area, entry to which none can relish
but which must be faced.
A secondary issue is how much influence
antibiotic administration has on the outcome
of pneumonia in elderly patients. The
scenario shows that it is considerable: my
experience over 30 years shows otherwise.
Michael H Yardley general practitioner
Lyngford Park Surgery, Fletcher Close, Taunton,
Somerset TA2 8SQ
mikeyardley@doctors.net.uk
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Maybe doctors do not always know best
Editor—The study by Thompson et al was a
timely examination of health professionals’
attitudes when the wishes of patients do not
match their own.1 Even after the recent judg-
ment in the case of Miss B it seems that many
of us are simply not prepared to allow
patients to refuse treatment they do not want.
In the case described by Thompson et al
the competently expressed wish of the patient
may be disregarded only if there is evidence
that her wishes have changed since the direc-
tive was signed. If not, once practitioners are
satisfied that the clinical circumstances match
those for which the directive provides (and
this is moot), then there is no moral, ethical,
or legal basis for disregarding her wishes.
Do we need further lawsuits before we
collectively accept that our role should not
include a paternalistic contempt for what
our patients want?
Philip S Jones specialist registrar in anaesthetics
Homerton Hospital, London E9 6SR
psjones@doctors.org.uk
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Advance directive needs to include
additional elements
Editor—Those of us who have made
advance directives can only be dismayed and
concerned by Thompson et al’s assumption
that there will always be ambiguity.1 Firstly,
doctors can strangely assume that patients
might aspire to spend their last days
demented in a residential home. Secondly,
this assumption is enough to justify giving
an antibiotic to prolong everyone’s agony,
mainly that of the patient.
Prescribing an antibiotic is the easy
option; many of us have done it. I will always
remember the withering look coupled with
the remark “Why did you do it?”of a most dis-
tinguished, very elderly lady to whom I
administered a parenteral antibiotic when
she was delirious with pneumonia. She recov-
ered and eventually developed dementia.
There was no alternative to the antibiotic:
there was no advance directive. Higgs
commented in the BMJ that pneumonia, the
old person’s friend, may be dismissed with a
wave of the prescribing pen—but what if the
old person wishes the friend to call?2
What can be done to counteract the
ambiguity? The hypothetical advance direc-
tive, although apparently fully comprehen-
sive and perhaps thought to be irrefutable,
should additionally include:
x A statement of general beliefs and aspects
of life that the person values. My own
statement is long and detailed and includes
the hope that I will not end up a burden tomy
carers, and that I will not have inflicted on me
a meaningless struggle against unacceptable
mental or physical disability by my doctors
x A statement naming a proxy who would
help the doctors with interpreting the
advance directive.
If my directive with these additions is still
ignored I hope that my relatives would not
hesitate to sue for assault or negligence.
George W Knox retired general practitioner
Burnham Overy Town, Norfolk PE31 8HU
george.knox@btopenworld.com
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Quality of life may be important in
advance directives
Editor—In the last paragraph of their
article Thompson et al highlight the fact
that the hypothetical advance directive
makes no reference to the quality of life.1
The reciprocal nature of the quality of life is
seldom considered, usually only an indi-
vidual perspective is taken. Western society
has focused increasingly and now almost
exclusively on the individual with regard to
gratification and now to life itself.
Monsignor Ronald Knox précised
Bishop Berkeley’s 18th century philosophy
with the following limerick.2
There was a young man who said “God
I find it exceedingly odd
that this very tree
Should continue to be
When there is no one about in the quad”
Answer
“Young man your question is odd.
I am always about in the quad.
And that’s why this tree
Continues to be”
Signed by, yours faithfully, God.
If one takes a humanist perspective, the
individual can be represented by the tree
having significance or quality by virtue of
another’s presence in the “quad.”
Oliver E Shanks consultant psychiatrist
19 Derryvolgie Avenue, Belfast BT9 6FN
oshanks@utvinternet.com
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Radiographic results are still
not routinely reported
Editor—Many clinicians will be surprised to
learn that hospitals in the United Kingdom
do not routinely report the results from all
plain radiographs before filing them. A con-
sultant radiologist recently told me that his
department does not report “a significant
proportion of radiographs” because there
are not enough resources to do so. They are
“working on a solution and hope that over
the next two or three years this practice will
have changed.” His department is in a
university teaching hospital and has 20 con-
sultant radiologists.
The Royal College of Radiologists has
been concerned by poor standards for some
years.1 In its audit of the reporting of inpatient
plain radiographs more than half of the hos-
pitals did not report all plain inpatient radio-
graphs, and 3% of hospitals did not report
any. In another audit of the reporting of
radiographs requested by general practition-
ers the standards set by the college were met
by only a minority of departments.
Although the regulations governing
medical exposure to ionising radiation
require the clinical evaluation of eachmedical
exposure to be recorded,2 radiology depart-
ments often fail to do so. In addition,
clinicians may not have robust systems for
detecting unreported radiographs that they
have requested. The inevitable consequence
is that many patients are exposed to inappro-
priate care, the risks of radiation without any
gain, and the possibility of further unneces-
sary radiation from more sophisticated tests.
These problems of risk management,
breaches of European Union directives, and
matters of clinical governance were clearly
identified three years ago by the Royal Col-
lege of Radiologists. Many clinicians seem
unaware that these problems exist and that
the solutions have not been implemented by
all hospital trusts.
Stephen C Bamber principal general practitioner
The Health Centre, Long Stratton, Norwich,
Norfolk NR15 2TS
stephen.bamber@nhs.net
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